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Background: We have been applying preoperative radiotherapy
(RT) to Masaoka stage III thymomas intending to make surgical
resection more complete by reducing mass volume, to prevent
possible dissemination caused by surgical manipulation and to get
better survival as a result. However, the radioresponses vary from
tumor to tumor. We hypothesized that thymoma is a variable
radioresponsive tumor depending on pretreatment histology.
Materials and Methods: Twenty-one of stage III thymomas under-
went preoperative RT plus surgery followed by postoperative RT
between 1982 and 2004. Reduction ratios, histopathologic changes
according to WHO histologic criteria, resectability, long-term sur-
vival, and disease control, by preoperative RT were analyzed.
Results: Pretreatment WHO subtypes were type AB (n 1), B1 (5),
B2 (6), B3 (4), and unclassified (5). Sixteen tumors (76.2%) de-
creased in size after preoperative RT with a mean (median) reduc-
tion ratio of 30.8% (27.0%). Type B1or B2 group had higher
reduction ratio than type B3 group (mean value of 39.7%, 31.8%,
and 21.0%, respectively, p  0.01). Histopathologically, lympho-
cyte diminished markedly in type B1 thymoma, and both lympho-
cyte and epithelial cells diminished in type B2, whereas none of the
B3 tumors showed any histologic change. The values of all the cases
is 90.5% in complete resection, 19.0% in no combined resection of
the adjacent organs, and 77.6% and 83.6% in overall and disease-
free 10-year survival, respectively, and these value do not differ
according to the WHO histologic criteria.
Conclusions: This modality at modest doses was macroscopically
and histopathologically effective on tumors particularly in WHO B1
and B2 thymomas than WHO B3 thymoma. The therapeutic benefit
of preoperative RT followed by surgery and postoperative RT for
stage III thymomas should be defined thoroughly.
Key Words: Preoperative radiotherapy, Thymoma, WHO, Masaoka
staging, Neoadjuvant.
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Thymoma is indolent in growth but potentially malignantin its clinical course because of invasion of neighboring-
organs, pleural dissemination, and occasional systemic me-
tastasis. Surgery and radiotherapy (RT) remain the mainstays
of the clinical management of thymoma. The Masaoka stag-
ing system (Table 1), which is based on the assessment of
tumor invasion by pretreatment examination, surgery, and
pathologic examinations, has been widely accepted for esti-
mating prognosis and for determining the adjuvant treat-
ments.1 According to the Masaoka staging system, surgery
alone is sufficient for treating the stage I or II diseases
(noninvasive or minimally invasive). In contrast, complete
resection may be possible in the stage III disease, resulting in
a 40 to 90% range in the 5-year survival rate.2–5 Postoperative
RT is required for the stage III disease (macroscopically
invasive) as an adjuvant therapy,6–8 although the need for this
modality is not supported by all reports.9 In addition, in
regard to stage III thymomas, pleural recurrence is a major
pattern of failure after complete resection. To improve clin-
ical results, various modalities such as preoperative chemo-
therapy and preoperative steroid pulse therapy have been
adapted as an induction therapy for the management of stage
III or IV thymomas, but no significant improvement has been
obtained with these modalities.10–14
The effectiveness of preoperative RT with invasive
thymomas was first documented by Sellors.15 Total thymec-
tomy and excision of involved tissues or organs became
easier because of tumor shrinkage or the decrease in tumor
bloodstream, induced by preoperative RT.15 In addition, some
reports showed the pleural dissemination that might occur
during surgical manipulation could be suppressed by preop-
erative RT.15–18 It has been thought that preoperative RT to
stage III thymomas improve the rate of complete resection,
reduce local and pleural recurrences, then, contribute to good
survival or disease control. We have performed preoperative
RT since 1982 to stage III thymomas based on these con-
cepts. However, the radioresponses vary from tumor to tumor
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and benefits to long-term survival and disease control are still
not clear.19–21
In 1999, the World Health Organization (WHO)
reached a consensus on the histologic criteria of thymoma
based on morphology and the lymphocyte-to-epithelial cell
ratio.22 This new histologic criteria has been proposed as a
predictor of prognosis by several retrospective studies, al-
though this had not been the case with previous histologic
classifications of thymoma.5,23–28 The WHO histologic crite-
ria was revised in 2004 (Table 2), but the concept of thy-
moma did not change.29 There have been few reports on
histologic radioresponse regarding thymomas.
We hypothesized that thymoma is variable radioresponse
tumor on pretreatment histology. The radio-resistant subgroups
of stage III thymomas may offset the advantage of the therapeu-
tic benefit by preoperative RT. The aim of this study is to
evaluate the radiologic and histopathologic response to preop-
erative RT according to new WHO histologic criteria. Second-
ary, surgical and survival benefit of preoperative RT followed by
surgery and postoperative RT is analyzed according to theWHO
histologic criteria and for all cases.
PATIENTS AND METHODS
Patients
This study included 21 patients with stage III thymo-
mas treated by preoperative RT and surgery. Subjects were
selected from 94 consecutive patients with thymic epithelial
tumors (81 thymomas and 13 thymic carcinomas) treated
between April 1982 and February 2004. These 94 tumors
were reclassified according to Masaoka staging system1 as
pretreatment clinical stage using computed tomographic (CT)
scans, and new WHO histologic criteria29 using biopsy or
surgical materials. The distributions of these tumors, accord-
ing to WHO criteria and Masaoka staging system, were similar
to other reports (Table 3).23–27 Pretreatment biopsy materials
were obtained by percutaneous needle biopsy under fluoroscopy
or CT guide or by incision biopsy. In each case, three patholo-
gists evaluated and agreed according to WHO criteria by re-
viewing hematoxylin-eosin stained sections from paraffin-
embedded blocks without knowing the patients’ clinical fea-
tures. Cases of poor material-preservation or the absence of
viable cells in the materials were classified as “unclassified.”
All patients gave their written informed consent to the
treatment methods. The Institutional Review Board of Uni-
versity of Tsukuba approved the study protocol. Clinical
records during RT and surgery, biopsy specimens and re-
sected materials, CT scan images, and follow-up data were
available. Those 21 thymomas of clinical stage III consisted
of 11 men and 10 women with ages ranging from 19 to 84
years (mean, 43.7 years; median, 47 years). Two patients had
myasthenia gravis.
Preoperative RT and Radiologic Radioresponse
Treatment consisted of preoperative RT, surgery, and
postoperative RT. The criterion for preoperative RT was the
apparent radiologic involvement of great vessels (the superior
vena cava, aorta, and brachiocephalic vein), the lung, or
pericardium, because the involvement of these organs often
leads to incomplete tumor resection or to combined resection
and reconstruction.
The radiation technique was described elsewhere,21 but
in brief, preoperative RT was performed using the telecobalt
(cobalt-60 gamma rays) in early period of this study or the
linac in late period, 6 MV or 10 MV roentgenogram. Antero-
posterior opposing portals or an anterior portal that covered the
whole mediastinum or the tumor mass visualized on CT scans
with a 1 to 2 cmmargin were used. Prescribed total doses ranged
from 12.0 to 20.0 Gy (mean, 18.5 Gy; median, 18.0 Gy),
administered at 1.2 to 2.0 Gy per fraction involving five fractions
per week.19–21 The portals encompassed the entire mediastinum
in the early period of the study or the tumors identified by CT
scans with generous margins in the late period.
The radioresponse of tumors was assessed radiologi-
cally as the reduction ratio calculated according to the
RECIST guidelines.30 As guidelines, we evaluated the tumor
TABLE 1. The Masaoka Staging System
Stage I Macroscopically completely encapsulated and
microscopically no capsular invasion
Stage II Macroscopic or microscopic invasion into surrounding
fatty tissue or mediastinal pleura
Stage III Macroscopic invasion into neighboring organ, i.e.,
pericardium, great vessels, or lung
Stage IVa Pleural or pericardial dissemination
Stage IVb Lymphatic or hematogeneous metastases
TABLE 2. The WHO Histologic Classification of Thymoma
Subtype
A Spindle cell: medullary
AB Mixed
B1 Lymphocyte-rich, lymphocytic predominantly cortical:
organoid
B2 Cortical
B3 Epithelial: atypycal: squamoid: well-defferentiated
thymic carcinoma
Others Micronodular thymoma, metaplastic thymoma,
microscopic thymoma, sclerosing thymoma, and
lipofibroadenoma
TABLE 3. WHO Histologic Subtypes and Masaoka Staging
System
WHO Subtype
Masaoka Staging System
TotalI II III IV
Thymoma
A 1 3 0 0 4
AB 7 8 1 0 16
B1 2 6 5 1 14
B2 9 8 6 4 27
B3 3 6 4 0 13
Unclassified 0 1 5 1 7
Thymic carcinoma 0 2 3 8 13
Total 22 34 24 14 94
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sizes based on coronal view by using CT scans obtained
before preoperative RT or before surgery. The reduction
ratios (%) of tumors by preoperative RT were calculated;
reduction ratio (%)  (1  tumor size at after preoperative
RT/tumor size at before preoperative RT)  100.
If diagnosed as stage III thymoma, preoperative RT
was induced at about 20 Gy. About 2 weeks after the
completion of RT, patients underwent CT to evaluate the
efficacy of the RT (reduction rate), and then total thymec-
tomy was performed.
Surgical Resection and Pathologic
Radioresponse
Surgical resection was performed from 7 to 21 days
(mean, 13.2; median, 13 days) after the completion of pre-
operative RT.19–21 Resection was classified into two types.
One was complete resection with total thymectomy with or
without combined resection of involved organs, and other
was incomplete resection resulting in a positive margin.
Pathologic radioresponse was assessed histopathologi-
cally, with surgical materials compared with pretreatment
biopsy materials. The surgical materials were also diagnosed
according to WHO histologic criteria. It was determined,
whether WHO subtypes were changed or not by the RT, or
whether or not there were any tendencies of histologic change
compared with the pretreatment WHO subtypes, or whether
the ratio of tumor epithelial cells and lymphocytes changed
after the RT, and so on.
Postsurgical Treatment
Eighteen patients underwent postoperative RT 13 to 49
days (median, 26 days) after the surgery, but the remaining
three did not because of either active pulmonary tuberculosis,
postoperative pericarditis, or patient’s will. The target volume
of postoperative RT was determined taking surgical and
pathologic findings into consideration. The total doses was
normally 22.0 to 66.8 Gy (median, 40.0 Gy; Table 4) over 4.5
weeks, with fraction size and fractionation similar to that in
preoperative RT. The total dose was modified in seven
patients according to the patient’s condition or tumor status
after surgery (Table 4).
The two patients with myasthenia gravis were treated
by oral corticosteroid throughout the thymoma treatment.
Follow-Up and Survival
Posttreatment follow-up was done with annual chest
radiograph and CT scan when necessary. The follow-up
period ranged from 6 to 178 months (mean, 68.2; median, 59
months). Overall survival and disease-free survival rates were
estimated by the Kaplan-Meier method setting the date of
thymectomy as the starting point.
Statistical Analysis
We analyzed the relation between the radiologic radio-
response (reduction ratio), resection type, histologic radiore-
sponse, and changes in stage and WHO histologic criteria
after the preoperative RT. The paired t test was used to test
TABLE 4. Characteristics of Tumors and Their Response to Radiotherapy
Patient
No.
WHO Subtype
Tumor
Size
(mm)
Preoperative
RT (Gy)
Reduction
Ratio (%)
Resection
Type
Pathologic
Stage
(after RT)
Postoperative
RT (Gy)
Clinical Outcome
Before
RT
After
RT
Disease
Control
Survival
(mo)
1 AB AB 110 18.0 0 Complete III 22.0 Yes Alive (12)
2 B1 AB 65 18.0 0 Complete II No (pat. will) Yes Alive (12)
3 B1 B2 62 20.0 26 Complete II 40.0 No Alive (45)
4 B1 B2 90 20.0 0 Complete III 41.0 Yes Alive (59)
5 B1 B2 92 18.0 43 Complete III 49.7 Yes Alive (16)
6 B1 B2 70 18.0 50 Complete II No (percarditis) Yes Alive (14)
7 B2 B2 (FT) 80 20.0 25 Complete III 44.0 Yes Alive (142)
8 B2 B2 (FT) 90 18.0 34 Complete III 41.4 Yes Alive (68)
9 B2 B2 (FT) 120 19.8 46 Complete III 40.0 Yes Alive (111)
10 B2 B2 (FT) 110 18.0 45 Complete III 41.4 Yes Alive (114)
11 B2 B2 (FT) 110 19.2 27 Complete III No (Tb.) Yes Alive (6)
12 B2 B2 75 18.0 14 Complete II 39.6 Yes Alive (25)
13 B3 B3 60 18.0 0 Complete III 39.6 Yes Alive (20)
14 B3 B3 75 18.0 0 Complete III 40.0 Yes Alive (22)
15 B3 B3 130 19.6 21 Complete III 61.6 Yes Alive (132)
16 B3 B3 90 20.0 22 Complete III 40.0 No Alive (69)
17 Unclass Unclass (FT) 170 18.0 30 Complete III 26.0 Yes Alive (173)
18 Unclass Unclass (FT) 160 18.4 24 Incomplete III 66.8 No Dead (108)
19 Unclass Unclass (NFT) 110 12.0 30 Complete III 39.9 Yes Alive (178)
20 Unclass Unclass (NFT) 120 18.8 30 Incomplete III 43.0 No Dead (10)
21 Unclass Unclass (NFT) 93 20.0 26 Complete III 40.0 Yes Alive (97)
RT, radiotherapy; unclass, unclassified; FT, fibrous tissue mostly; NFT, necrotic fibrous tissue; pat. will, patient’s will; Tb., tuberculosis.
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the difference in the reduction ratio between the WHO
subtypes. Analyses were performed by using the statistical
program SPSS version 11.5 (Chicago, GA: SPSS). p Values
of less than 0.05 were considered statistically significant.
RESULTS
Pretreatment WHO Classification and
Radiologic Radioresponse
WHO histologic criteria of thymomas before preoper-
ative RT were determined as type AB (n 1), B1 (n 5), B2
(n  6), B3 (n  4), and “unclassified ” (n  5) (Table 4).
All but five thymomas responded to the preoperative
RT (76.2%) with a mean (median) reduction ratio of 30.8%
(27.0%) (range, 14.0–50.0%; Table 4). Chest CT scans of a
typical case in which preoperative RT was effective (patients
no. 9) are shown as an example (Figure 1). No radioresponse
was observed in the five thymomas, on WHO histologic
criteria, which were 1 type AB, 2 type B1, and 2 type B3
thymomas. The reduction ratio of type B1 (range, 26.0–
50.0%; mean, 39.7%; median, 43.0%) and B2 (range, 14.0–
46.0%; mean, 31.8%; median, 34.0%) were significantly
higher than that of type B3 (range, 21.0–22.0%; mean,
21.5%; median, 21.0%) (p  0.01).
Histopathologic Changes after Preoperative RT
Histopathologic changes after preoperative RT were
assessable in 16 thymomas excluding the five that were
classified as unclassified before treatment. The RT-induced
histologic alternations were prominent in type B1 and B2
thymomas (Figure 2A–D). Lymphocytes diminished mark-
edly in four of five pretreatment type B1 thymomas that
consisted of numerous lymphocytes and a few epithelial
tumor cells changing to near-type B2 in terms of proportion
of tumor epithelial cells and lymphocytes (Table 4). The
typical case of the B1 type changing with preoperative RT
was patient 3 in Table 4. The findings in Figure 2A, the
biopsy material of this case, changed to 2B which is surgical
materials. The remaining pretreatment type B1 thymoma
changed to type AB. Five of six pretreatment type B2 thy-
momas showed diffuse fibrous change with scanty lympho-
cytes and epithelial tumor cells after preoperative RT (Table
4). The typical case of type B2 changing with RT was patient
8 in Table 4. The findings in Figure 2C changed to 2D. The
remaining pretreatment B2 thymoma with a low reduction
ratio of 14% remained type B2 after RT, with histologic
findings similar to those before RT. In contrast, none of the
four pretreatment type B3 thymomas showed any obvious
histologic changes after preoperative RT (Table 4). Figures
2E and F show type B3 biopsy and surgical materials,
respectively.
Resection Type
Complete resection was achieved in all but two patients
(90.5%) (Table 4). These two patients underwent incomplete
resection, because of macroscopic residual at the epicardium
that was unresectable. The superior vena cava was recon-
structed by using an artificial graft after combined resection
(n 3). Resection of the organ considered to be involved was
avoided in 4 of 21 patients (19.0%). The tumors of these four
patients were evaluated pathologically as stage II disease,
because no neighboring organs were resected. The number of
organs considered to require combined resection before RT
decreased in 12 patients (57.1%).
Clinical Outcomes
Two patients (numbers 18 and 20 in Table 4) who
underwent incomplete resection died of tumor recurrence at
the surgical margin after 108 and 10 months. Two of 19
patients, numbers 3 and 16 in Table 4, who underwent
complete resection, presented recurrence as pleural dissemi-
nation after 20 and 43 months. Progression of myasthenia
gravis was associated with the recurrence in both these
patients, one of whom had been evaluated as pathologic stage
II because no neighboring organs were resected at total
thymectomy. These patients with recurrence are presently
alive without disease after resection of disseminations and
chemotherapy. Their observation periods from total thymec-
tomy were 45 and 69 months, respectively.
Overall and disease-free survival curves are shown in
Figures 3 and 4. Overall survival rates were 90.5% and 77.6%
FIGURE 1. Computed tomographic scans of a 35-year-old
man with stage III thymoma (WHO type B2, patient No 9 in
Table 4), who is alive without disease 111 months after
complete resection and superior vena cava (SVC) grafting. A
huge mass of thymoma occupying the entire anterior medi-
astinum obstructed SVC before treatment (A). The tumor
size decreased markedly (reduction ratio, 46%) after preop-
erative radiotherapy (19.8 Gy) (B).
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FIGURE 3. Overall survival curve of thymoma patients
(n  21).
FIGURE 4. Disease-free survival curve of thymoma patients
having undergone complete resection (n  19). Patients
having undergone incomplete resection (n  2) are
excluded.
FIGURE 2. Comparison of histologic
findings of thymomas according to
the WHO classification groups before
and after preoperative radiotherapy.
Microscopic views (H&E stain) of nee-
dle biopsy materials before radiother-
apy (A, C, E) and corresponding views
of surgical materials after radiotherapy
(B, D, F) are shown. The histologic
findings classified as WHO type B1 (A)
changed to that as B2-like tissue (B),
and true B2 (C) to fibrous tissue (D),
although B3 did not show any re-
markable change after preoperative
radiotherapy (E, F).
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at 5 and 10 years, respectively, and disease-free rates exclud-
ing the two incomplete-resection patients (n  19) are 83.6%
and 83.6%, respectively.
DISCUSSION
We have used preoperative RT in rather small doses
(18–20 Gy) in expectation of increasing the rate of complete
resection, and reducing possible pleural dissemination during
surgical manipulation, while avoiding making resection dif-
ficult because of RT induced fibrosis that could occur with
high doses. Sellors et al. showed effectiveness of preoperative
RT in thymoma patients.15 But their dose as preoperative RT
was larger than ours, and ranged from 40 to 60 Gy. They
reported that the tumors became less extensive but that the
operation was technically difficult, which might have been
because of the high radiation doses.15 Our modality of limited
dose preoperative RT is feasible and time saving compared
with preoperative chemotherapy.10,11,31 For example, ADOC,
which consists of the intravenous administration of adriamy-
cin, cisplatin, vincristine, and cyclophosphamide, requires
about 3 months when 1 cycle takes 3 weeks and 4 cycles are
to be performed.11 Our complete resection rate of 90.5% is
higher compared with reported rates of 60 to 90% without
preoperative RT.3,11,16,31 Besides, preoperative RT might
have induced down staging to stage II in four patients.
However, two patients failed to undergo complete resection,
and died because of tumor regrowth after postoperative RT.
This fact suggests that achievement of complete resection is
an important key to disease control.
Overall and disease-free survival rates of stage III
thymoma, collected from other studies in which preoperative
RT was not used, are listed in Table 5. Our overall and
disease-free survival rates are higher than others,1–5,16,32–36
due probably to our high complete resection rate. However,
our four down-staged tumors could have been overestimated,
i.e., these tumors might have been primarily stage II disease.
There is a limitation on preoperative estimation of organ
involvement.
Yagi and associates performed preoperative RT with
doses of 20 to 66 Gy for nine patients with stage III or IV
thymomas, and found that there was no significant difference
in survival rate in stage III patients between those with and
without preoperative RT, although complete resection had
become easier after preoperative RT.18 Shamji and associates
reported that preoperative RT might have prevented thoracic
dissemination during surgery, but its effectiveness is not well
proved.17 Myojin and associates demonstrated that all pleural
recurrences were observed among stage III patients who were
treated without presurgical treatment.16 In addition, they
suggested that preoperative RT or chemoradiotherapy im-
proved survival by facilitating complete resection and by
reducing local and pleural recurrences.16
Response rates of thymomas to preoperative chemo-
therapy were reported as 77 to 100%, but pathologic com-
plete resection rates remained at lower levels of 4 to 31%
compared with ours.3,10–13,37 Preoperative corticosteroid was
reported to induce lymphocyte-apoptosis.14,38 The cell killing
effect of corticosteroid on epithelial thymoma cells is con-
troversial,39,40 whereas the effect of radiation is evident.
Although there is no clear consensus on the best induction
therapy for invasive thymomas,10 preoperative RT may be
considered more reliable than corticosteroids or chemother-
apy as a preoperative treatment for stage III thymomas.
In this study, almost cases had also received postop-
erative RT as adjuvant therapy. So, it could not be said that
only the preoperative RT contributed readily to good
overall or disease-free survival. That is to say, the combi-
nation therapy for stage III thymomas, which consisted of
preoperative RT, total thymectomy and postoperative RT,
could contribute to good results. However, it is difficult to
evaluate that in this study.
There is not much argument about radioresponse or
radiation-induced histologic changes of thymomas. Our pre-
vious study has demonstrated that lymphocytes in thymomas
tended to drop out after preoperative RT, but the reduction
ratio did not differ between the subtypes according to Rosai’s
histologic classification.21 However, our present study using
the WHO histologic criteria shows significant difference in
the reduction ratio among the subtypes: the reduction ratio
was significantly lower in type B3 thymomas than in type B1
or B2 thymomas. Histologically, lymphocytes markedly de-
creased in type B1 thymomas after RT, resembling the
reported effects of corticosteroid,14 and lymphocytes are
known as some of the most radiosensitive cells. Therefore,
type B1 or B2 thymomas that resulted in the relative predom-
inance of the epithelial component after RT or corticosteroid
treatment could be mistaken for type B3 thymomas.41 Be-
sides, most type B2 thymomas showed diffuse fibrous change
TABLE 5. Comparison of Overall and Disease-Free Survival
Rates in Patients with Stage III Thymoma
Authors n
Overall Survival
n
Disease-free
Survival
10-yr Rate
(%)
5-yr Rate
(%)
10-yr Rate
(%)
This Study (2006)
Clinical Stage III 21 90.5 77.6 19 83.6
(88.2a, 65.8b)
Kondo et al. (2003) 204 88.7 78.0c 143 72.7a
Nakagawa et al. (2003) 25 81.0 76.0 –– ––
Venuta et al. (2003)
Cortical thymoma 23 –– 84.2 23 70.6b
WDTC 11 –– 90.9 11 60.0b
Ogawa et al. (2001) 25 48.0 48.0 25 56.0a
Myojin et al. (2000) 32 71.0 54.0 –– ––
Pan et al. (1994) 27 63.0 58.0 –– ––
Pescarmana et al. (1990) 26 55.0c 40.0c –– ––
Nakahara et al. (1988) 48 87.8 77.2 –– ––
Cowen et al. (1995)d –– –– –– 46 77.0
Monden et al. (1985) –– –– –– 44 73.0a
Masaoka et al. (1981) 31 69.6 58.3 –– ––
a All disease-free survivors included.
b Incomplete resection was involved.
c The survival rates were calculated from the survival curves.
d The stages were determined using GETT staging system.
PreRT, preoperative radiotherapy; WDTC, well-differentiated thymic carcinoma.
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with a few lymphocytes and epithelial tumor cells after
preoperative RT. A reason for this is thought that fibrous
stroma which originally existed in B2 thymomas remain after
depletion of the cellular components of lymphocytes and
epithelial cells. In contrast, type B3 thymomas show no
obvious histologic change after RT. The difference in histo-
logic changes after RT between type B2 and B3 thymomas
may be attributable to the difference in the radioresponse of
their epithelial tumor cells. The poor radioresponse of type
B3 thymomas may predict a poor effect of postoperative RT
on the remaining microscopic or macroscopic tumor cells.
Small biopsy specimens may not always be reliable for
WHO histologic criteria because of histologic heterogeneity
within a tumor. However, with our experience treating stage
I and II thymomas, we found that biopsy specimens were
almost always consistent with the surgical materials in the
criteria (data not shown).
In conclusion, preoperative RT was effective in reduc-
ing the tumor size, facilitating complete resection of stage III
thymomas. The effect, however, differs among the subtypes
of WHO histologic criteria: both type B1 and B2 thymomas
were significantly better than type B3 thymomas in both
radiologic and histologic radioresponse.
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